Experimental drug offers hope for patients with unstoppable seizures

This trial provided expanded access to an experimental drug called SAGE-547 for patients with super-refractory status epilepticus—a life-threatening condition where seizures continue despite multiple standard treatments. The study aimed to see if continuous intravenous infusion of SAGE-547 could help stop these dangerous seizures and was safe for patients aged six months and older who were in intensive care. It specifically included patients who had already failed to respond to first- and second-line anti-seizure medications.